372 related articles for article (PubMed ID: 21623238)
41. Lymph node ratio may predict the benefit of postoperative radiotherapy in non-small-cell lung cancer.
Urban D; Bar J; Solomon B; Ball D
J Thorac Oncol; 2013 Jul; 8(7):940-6. PubMed ID: 23695418
[TBL] [Abstract][Full Text] [Related]
42. Correlation and coexpression of HIFs and NOTCH markers in NSCLC.
Andersen S; Donnem T; Al-Saad S; Al-Shibli K; Stenvold H; Busund LT; Bremnes RM
Anticancer Res; 2011 May; 31(5):1603-6. PubMed ID: 21617216
[TBL] [Abstract][Full Text] [Related]
43. Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer.
Hyogotani A; Ito K; Yoshida K; Izumi H; Kohno K; Amano J
Clin Lung Cancer; 2012 Sep; 13(5):375-84. PubMed ID: 22284440
[TBL] [Abstract][Full Text] [Related]
44. Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites.
Gomez-Roca C; Raynaud CM; Penault-Llorca F; Mercier O; Commo F; Morat L; Sabatier L; Dartevelle P; Taranchon E; Besse B; Validire P; Italiano A; Soria JC
J Thorac Oncol; 2009 Oct; 4(10):1212-20. PubMed ID: 19687761
[TBL] [Abstract][Full Text] [Related]
45. [Expression of granulocyte colony stimulating factor in patients with non-small cell lung cancer and its clinicopathological significance].
Wei LX; Chang WL; Guo AT; Tai YH; Sun L; Shi HY
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):721-5. PubMed ID: 22336152
[TBL] [Abstract][Full Text] [Related]
46. Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: No association with prognosis identified in 3-year follow-up.
Toomey D; Smyth G; Condron C; Kelly J; Byrne AM; Kay E; Conroy RM; Broe P; Bouchier-Hayes D
Int J Cancer; 2003 Jan; 103(3):408-12. PubMed ID: 12471625
[TBL] [Abstract][Full Text] [Related]
47. L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer.
Imai H; Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
Histopathology; 2009 Jun; 54(7):804-13. PubMed ID: 19635099
[TBL] [Abstract][Full Text] [Related]
48. Overexpression of muscarinic receptor 3 promotes metastasis and predicts poor prognosis in non-small-cell lung cancer.
Lin G; Sun L; Wang R; Guo Y; Xie C
J Thorac Oncol; 2014 Feb; 9(2):170-8. PubMed ID: 24419413
[TBL] [Abstract][Full Text] [Related]
49. The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer.
Gottlin EB; Bentley RC; Campa MJ; Pisetsky DS; Herndon JE; Patz EF
J Thorac Oncol; 2011 Oct; 6(10):1687-90. PubMed ID: 21642860
[TBL] [Abstract][Full Text] [Related]
50. Polycomb group oncogene RING1 is over-expressed in non-small cell lung cancer.
Zhou Y; Wan C; Liu Y; Lv L; Chen B; Ni R; Huang Y; Li Y; Zheng X; Yang D; Mao G; Xue Q
Pathol Oncol Res; 2014 Jul; 20(3):549-56. PubMed ID: 24414991
[TBL] [Abstract][Full Text] [Related]
51. Node-negative non-small cell lung cancer: pathological staging and survival in 1765 consecutive cases.
Robinson BM; Kennedy C; McLean J; McCaughan BC
J Thorac Oncol; 2011 Oct; 6(10):1691-6. PubMed ID: 21869717
[TBL] [Abstract][Full Text] [Related]
52. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens.
Loo PS; Thomas SC; Nicolson MC; Fyfe MN; Kerr KM
J Thorac Oncol; 2010 Apr; 5(4):442-7. PubMed ID: 20195168
[TBL] [Abstract][Full Text] [Related]
53. GOLPH3 high expression predicts poor prognosis in patients with resected non-small cell lung cancer: an immunohistochemical analysis.
Zhang Y; Ma M; Han B
Tumour Biol; 2014 Nov; 35(11):10833-9. PubMed ID: 25081375
[TBL] [Abstract][Full Text] [Related]
54. Japanese Lung Cancer Registry Study: first prospective enrollment of a large number of surgical and nonsurgical cases in 2002.
Sawabata N; Asamura H; Goya T; Mori M; Nakanishi Y; Eguchi K; Koshiishi Y; Okumura M; Miyaoka E; Fujii Y;
J Thorac Oncol; 2010 Sep; 5(9):1369-75. PubMed ID: 20683209
[TBL] [Abstract][Full Text] [Related]
55. CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification.
Lee HJ; Choe G; Jheon S; Sung SW; Lee CT; Chung JH
J Thorac Oncol; 2010 May; 5(5):649-57. PubMed ID: 20354454
[TBL] [Abstract][Full Text] [Related]
56. HSP90B1 overexpression predicts poor prognosis in NSCLC patients.
Xu Y; Chen Z; Zhang G; Xi Y; Sun R; Wang X; Wang W; Chai F; Li X
Tumour Biol; 2016 Oct; 37(10):14321-14328. PubMed ID: 27599983
[TBL] [Abstract][Full Text] [Related]
57. Clinical significance of SH2B1 adaptor protein expression in non-small cell lung cancer.
Zhang H; Duan CJ; Chen W; Wang SQ; Zhang SK; Dong S; Cheng YD; Zhang CF
Asian Pac J Cancer Prev; 2012; 13(5):2355-62. PubMed ID: 22901222
[TBL] [Abstract][Full Text] [Related]
58. Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases.
Tran TN; Selinger CI; Kohonen-Corish MR; McCaughan B; Kennedy C; O'Toole SA; Cooper WA
Clin Lung Cancer; 2016 Jan; 17(1):30-8.e1. PubMed ID: 26395411
[TBL] [Abstract][Full Text] [Related]
59. Pathobiological implications of MUC4 in non-small-cell lung cancer.
Majhi PD; Lakshmanan I; Ponnusamy MP; Jain M; Das S; Kaur S; Shimizu ST; West WW; Johansson SL; Smith LM; Yu F; Rolle CE; Sharma P; Carey GB; Batra SK; Ganti AK
J Thorac Oncol; 2013 Apr; 8(4):398-407. PubMed ID: 23370366
[TBL] [Abstract][Full Text] [Related]
60. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer.
Morgensztern D; Waqar S; Subramanian J; Trinkaus K; Govindan R
J Thorac Oncol; 2012 Oct; 7(10):1485-9. PubMed ID: 22982649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
